[HTML][HTML] Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in canada: a descriptive analysis of real-world data
V Gitman, A Stavropoulos, V Saenz… - Multiple Sclerosis and …, 2022 - Elsevier
Objectives To report and describe the real-world use of ocrelizumab in women with multiple
sclerosis (MS) in Canada before and/or during pregnancy as well as their fetal outcomes …
sclerosis (MS) in Canada before and/or during pregnancy as well as their fetal outcomes …
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Objective To assess the onset of ocrelizumab efficacy on brain MRI measures of disease
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …
[HTML][HTML] Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
Background Ocrelizumab is an approved MS treatment administered as two 300-mg
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours …
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours …
[HTML][HTML] Antibody therapies for progressive multiple sclerosis and for promoting repair
J Havla, R Hohlfeld - Neurotherapeutics, 2022 - Elsevier
Progressive multiple sclerosis (PMS) is clinically distinct from relapsing–remitting MS
(RRMS). In PMS, clinical disability progression occurs independently of relapse activity …
(RRMS). In PMS, clinical disability progression occurs independently of relapse activity …
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database
K Hellwig, C Oreja-Guevara, S Vukusic… - Multiple Sclerosis and …, 2023 - Elsevier
Background/Objective (s) Approved labels advise that women with multiple sclerosis (MS)
use contraception during treatment with ocrelizumab (OCR) and for 6–12 months thereafter; …
use contraception during treatment with ocrelizumab (OCR) and for 6–12 months thereafter; …
B cell depletion in the treatment of multiple sclerosis
KM Myhr, Ø Torkildsen, A Lossius, L Bø… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …
Anti-CD20 cell therapies in multiple sclerosis—a fixed dosing schedule for ocrelizumab is overkill
J Avasarala - Drug Target Insights, 2017 - journals.sagepub.com
Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based
singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech …
singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech …
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
JS Wolinsky, NJ Engmann, J Pei… - Multiple Sclerosis …, 2020 - journals.sagepub.com
Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease
progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary …
progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary …
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary …
P Vermersch, C Oreja‐Guevara, A Siva… - European Journal of …, 2022 - Wiley Online Library
Background and purpose Using the treatment goal of “no evidence of disease
activity”(NEDA) incorporating magnetic resonance imaging (MRI) re‐baselining, we aimed …
activity”(NEDA) incorporating magnetic resonance imaging (MRI) re‐baselining, we aimed …
Novel monoclonal antibodies for therapy of multiple sclerosis
Introduction: Monoclonal antibodies play an important role in the therapy of different
autoimmune diseases. With the introduction of natalizumab, the importance of monoclonal …
autoimmune diseases. With the introduction of natalizumab, the importance of monoclonal …